1. Government of Ireland (Oireachtas). Health (Pricing and Supply of Medical Goods) Act 2013, Number 14. Irish Statute Book. Dublin: Office of the Attorney General; 2013. http://www.irishstatutebook.ie/eli/2013/act/14/schedule/3/enacted/en/html#sched3. Accessed 4 Oct 2021.
2. Barry M, Heerey A, Hughes C, McCulloch D, Merry C, Ryan M, et al. The Irish National Centre of pharmacoeconomics: its rationale and role. IMJ. 1999;92(4):337–9.
3. Directive 2013/50/EU of the European Parliament and of the Council of 22 October 2013 amending Directive 2004/109/EC of the European Parliament and of the Council on the harmonisation of transparency requirements in relation to information about issuers whose securities are admitted to trading on a regulated market, Directive 2003/71/EC of the European Parliament and of the Council on the prospectus to be published when securities are offered to the public or admitted to trading and Commission Directive 2007/14/EC laying down detailed rules for the implementation of certain provisions of Directive 2004/109/EC. OJ L 294, 6.11.2013, p. 13–27. https://eurlex.europa.eu/legal-content/EN/TXT/?uri=uriserv%3AOJ.L_.2013.294.01.0013.01.ENG&toc=OJ%3AL%3A2013%3A294%3ATOC. Accessed 4 Oct 2021.
4. Irish Pharmaceutical Healthcare Association, Health Services Executive. Framework agreement on the supply and pricing of medicines 2016. 2016. https://www.hse.ie/eng/about/who/cpu/iphaagreement2016.pdf. Accessed 23 Sep 2021.
5. McCullagh L, Barry M. The pharmacoeconomic evaluation process in Ireland. Pharmacoeconomics. 2016;34(12):1267–76.